Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Exploratory study evaluating the potential of immune signature profiling for predicting
response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous
Non-Small Cell Lung Cancer (NSCLC) to neoadjuvant ATEZOLIZUMAB plus Carboplatin/nab
Paclitaxel
Atezolizumab is given as intravenous infusion at a fixed dose of 1200 mg, day 1 of each
21-day cycle (every 3 weeks) for 3 cycles during the neoadjuvant treatment phase, Carboplatin
at an initial dose of AUC 5 mg/mL/min, intravenously day 1 of each 21-day cycle for 3 cycles
during the neoadjuvant treatment Phase, and Nab-Paclitaxel (Abraxane) at 100 mg/m2,
intravenously day 1, 8 and 15 of each 21-day cycle for 3 cycles during the neoadjuvant
treatment phase. Surgery after the 3rd cycle Atezolizumab / Carboplatin / Nab-Paclitaxel is
standard procedure.